Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
10/26/2022* -- Results Q3 2022 -- 1.94 --
10/26/2022* 09:00 EST Earnings Call Q3 2022 -- -- --
08/04/2022 -- Results Q2 2022 1.25 1.71 -26.75%
08/04/2022 09:00 EST Earnings Call Q2 2022 -- -- --
04/28/2022 -- Results Q1 2022 2.62 2.30 13.72%
04/28/2022 09:00 EST Earnings Call Q1 2022 -- -- --
02/03/2022 -- Results Q4 2021 2.49 2.51 -0.67%
02/03/2022 09:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 10/26/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/04/2022
Beat/Miss Upgrade
Return Since 8.84%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
URL https://www.lilly.com
Investor Relations URL https://investor.lilly.com/
HQ State/Province Indiana
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Growth
Next Earnings Release Oct. 26, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Aug. 12, 2022

Dividends

Dividend Per Share (TTM) 3.66
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.7777
Yield to Sector 0.619
Yield to Industry 0.309
Last Dividend Amt. 0.98
Dividend Frequency Quarterly
Last Ex-Dividend Date Aug. 12, 2022
Yield (TTM) 1.14%
Forward Yield 1.18%
Payout Ratio 58.21%
Cash Payout Ratio 66.93%
Consistent Payer (5Y) Yes
Consistent Growth (5Y) Yes

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
25.37%
-10.37%
17.83%
40.45%
16.15%
31.06%
66.08%
21.41%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-19.66%
32.33%
-32.38%
2.42%
-0.65%
0.53%
28.66%
30.72%
18.08%
-9.75%
-7.43%
21.96%
-5.54%
-1.39%
-17.48%
-2.02%
9.07%
1.16%
15.32%
24.40%
-5.14%
16.21%
10.85%
11.45%
-1.59%
-3.72%
15.23%
-1.33%
40.20%
22.42%
-7.07%
1.86%
18.24%
As of October 05, 2022.

Profile

Edit
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
URL https://www.lilly.com
Investor Relations URL https://investor.lilly.com/
HQ State/Province Indiana
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Growth
Next Earnings Release Oct. 26, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Aug. 12, 2022

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
VPMCX 5.186B USD 8.65%
VGHCX 2.752B USD 6.06%
XLV 2.043B USD 5.46%
VIVAX 2.254B USD 1.57%
VTV 2.254B USD 1.57%
IVV 2.314B USD 0.85%
SPY 2.831B USD 0.81%
FXAIX 2.792B USD 0.74%
VFINX 5.341B USD 0.71%
VOO 5.341B USD 0.71%
VTSMX 7.642B USD 0.65%
VTI 7.642B USD 0.65%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter LLY Tweets